The takeover, reportedly worth $2.9 billion, adds LifeCell's regeneration medicines, including its portfolio of dermal matrix products, to the Allergan's aesthetic portfolio.

Products include Acellulat Dermal Matrices, commonly used in breast reconstruction, as well as ALLODERM, a human allograft tissue matrix used in breast reconstruction post-masectomy and RESOLVE, a single use high-volume fat grafting device used in plastic and reconstructive procedures.

"The completion of the LifeCell acquisition is an important milestone for Allergan, serving as our entry point into regenerative medicine as we continue to add to our world-class aesthetic and plastic surgery business," said Brent Saunders, chairman and CEO of Allergan. "The combination of LifeCell's novel regenerative medicine products coupled with Allergan's innovative medical aesthetics and plastic surgery portfolio creates a more complete product offering for plastic surgeons globally."